/
ESPR
$3.15-$0.02 (-0.63%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$816.9M
258M shares
52-week range
$0.95 – $4.18
68% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-18.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $184.5M | $148.4M | $227.5M | $78.4M | $75.5M | $116.3M | $332.3M | $403.1M |
| Cost of revenue | $265.0K | $0 | $2.4M | $14.2M | $27.0M | $43.3M | $68.6M | $129.2M |
| Gross profit | $184.2M | $148.4M | $225.2M | $64.2M | $48.5M | $73.1M | $263.7M | $273.9M |
| Gross margin | 99.9% | 100.0% | 98.9% | 81.9% | 64.3% | 62.8% | 79.4% | 67.9% |
| R&D | $171.5M | $175.6M | $146.9M | $106.0M | $118.9M | $86.1M | $46.2M | $47.9M |
| Operating income | −$204.6M | −$93.1M | −$121.4M | −$226.7M | −$179.5M | −$155.6M | $54.4M | $60.3M |
| EBITDA | −$204.3M | −$88.7M | −$120.3M | −$222.1M | −$176.3M | −$150.1M | $7.6M | $63.9M |
| Net income | −$201.8M | −$97.2M | −$143.6M | −$269.1M | −$233.7M | −$209.2M | −$51.7M | −$22.7M |
| Net margin | -109.4% | -65.5% | -63.1% | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
| EPS (diluted) | -7.54 | -4.02 | -6.05 | -11.03 | -4.33 | -2.03 | -0.28 | -0.11 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $388M | $-0.04 | $-0.05–$-0.03 | 2 |
| 2027 | $449M | $0.27 | $0.25–$0.31 | 4 |
| 2028 | $505M | $0.43 | $-0.61–$1.21 | 4 |
| 2029 | $659M | $0.51 | $0.41–$0.58 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Esperion Therapeutics, Inc.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
www.esperion.com- Employees
- 294
- IPO / List date
- Jun 26, 2013
- HQ
- ANN ARBOR, MI
Held by traders on TradeandTell
No one on the platform currently holds ESPR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,620,100 | $4.4M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2013-06-11 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded ESPR yet.
